Watch Myriad Genetics’ ESMO 2022 Industry Satellite Symposium
Should we use genetic signatures for chemotherapy decisions in ER+/HER2- premenopausal patients?
Dr. Anastasia Constantinidou shares key new data from ESMO Congress 2022 demonstrating how EndoPredict can help guide treatment decisions and avoid overtreatment for premenopausal women with ER+, HER2- early breast cancer.
Watch Myriad Genetics’ ESMO 2022 Industry Satellite Symposium video below titled, “Controversies in breast and ovarian cancer genetics.”
